In August, all Wegovy doses except for 0.25mg and all doses of Ozempic, Zepbound, and Mounjaro were marked available according to the FDAs list
As importantly, GLP-1 driven improvements in morbidity and mortality across so many conditions and patient populations strongly impacts the overall risk-reward calculation for prescribers considering a GLP-1 for a patient with SUD
Clinical trial data supports continuous semaglutide use for at least 23 years with sustained safety and efficacy
Read more Insurance covers Mounjaro only for diabetes for weight loss, here's a path that skips insurance Kaiser covers Mounjaro for diabetes only, behind a semaglutide-first step, and excludes weight-loss GLP-1s on Medi-Cal from 1/1/2026
Localised itching at injection sites is a recognised common adverse effect of Ozempic, affecting between 1 in 10 and 1 in 100 people
The carbs and fats can wait